Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Go back to Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting| (NASDAQ: CBIO) | Delayed: 18.00 +0.43 (2.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.57 | 52 Week High | $4.57 | |||
| Open | $17.00 | 52 Week Low | $0.62 | |||
| Day High | $18.16 | P/E | N/A | |||
| Day Low | $16.80 | EPS | $0.00 | |||
| Volume | 93,061 | |||||
